Oxford BioMedica (LON:OXB)‘s stock had its “buy” rating reiterated by equities research analysts at Peel Hunt in a research report issued to clients and investors on Tuesday, August 28th.
Separately, Jefferies Financial Group downgraded Oxford BioMedica to a “hold” rating in a report on Wednesday, June 13th.
Oxford BioMedica stock traded down GBX 11.80 ($0.15) on Tuesday, hitting GBX 842.80 ($10.87). 29,449 shares of the stock traded hands, compared to its average volume of 6,890,000. Oxford BioMedica has a 1 year low of GBX 4.44 ($0.06) and a 1 year high of GBX 13.19 ($0.17).
In related news, insider John Dawson sold 10,046 shares of Oxford BioMedica stock in a transaction dated Tuesday, August 7th. The stock was sold at an average price of GBX 890 ($11.48), for a total value of £89,409.40 ($115,337.20). Also, insider Lorenzo Tallarigo acquired 262 shares of Oxford BioMedica stock in a transaction that occurred on Friday, June 22nd. The stock was acquired at an average price of GBX 1,019 ($13.14) per share, with a total value of £2,669.78 ($3,443.99). Insiders have bought 870 shares of company stock valued at $798,342 over the last 90 days.
Oxford BioMedica Company Profile
Oxford BioMedica plc, a biopharmaceutical company, engages in the research, development, and bioprocessing of lentiviral vector and cell therapy products for the treatment of various cancers, Parkinson's, central nervous system disorders, and ocular conditions in Europe and internationally. The company operates through Platform and Product segments.
See Also: Hedge Funds Explained
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.